"$2B / 5 equals avg of 400M per year. Apply that with a PE of 10 gives a market cap 4B."
That is indeed one conservative PE ratio - the average for the biotech industry on the ASX is 46 which on the 'lower side' of that average is CSL with a PE of 37, so that's your conservative base case. For contrast, Telix has a PE of 124. Pretty much pick any number well north of 50 for the PE for any ASX biotech that gets their first drug to market.
Ann: Security Class Reinstatement to Quotation- OPTOB, page-210
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.5¢ |
Change
-0.045(6.43%) |
Mkt cap ! $806.3M | |||
| Open | High | Low | Value | Volume |
| 69.5¢ | 69.5¢ | 63.0¢ | $2.808M | 4.305M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49996 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 50869 | 6 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |